These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 37551495)

  • 1. [Efficacy and Safety of Bendamustine in the Conditioning Regiment for Autologous Hematopoietic Stem Cell Transplantation in Patients with Lymphoma].
    Fu Y; Feng YF; Liu F; Chen QL; Zhang WJ; Li QF; Wei XF; Zhang QK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(4):1179-1183. PubMed ID: 37551495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation.
    Colita A; Colita A; Bumbea H; Croitoru A; Orban C; Lipan LE; Craciun OG; Soare D; Ghimici C; Manolache R; Gelatu I; Vladareanu AM; Pasca S; Teodorescu P; Dima D; Lupu A; Coriu D; Tomuleasa C; Tanase A
    Front Oncol; 2019; 9():892. PubMed ID: 31552193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the Efficacy of Modified BeEAM(Bendamustine, Etoposide, Cytarabine, Melphalan) Regimen as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Lymphoma: An Experience from Two Centers of a Developing Country.
    Ramzi M; Vafaie E; Haghighinejad H; Imran H
    Int J Hematol Oncol Stem Cell Res; 2023 Apr; 17(2):106-113. PubMed ID: 37637764
    [No Abstract]   [Full Text] [Related]  

  • 4. BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients.
    Gilli S; Novak U; Taleghani BM; Baerlocher GM; Leibundgut K; Banz Y; Zander T; Betticher D; Egger T; Rauch D; Pabst T
    Ann Hematol; 2017 Mar; 96(3):421-429. PubMed ID: 28011985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
    Saleh K; Danu A; Koscielny S; Legoupil C; Pilorge S; Castilla-Llorente C; Ghez D; Lazarovici J; Michot JM; Khalife-Saleh N; Lapierre V; Alenxandrova K; Arfi-Rouche J; Bourhis JH; Ribrag V
    Leuk Lymphoma; 2018 Nov; 59(11):2580-2587. PubMed ID: 29164977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Z-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphoma.
    Tardy MP; Gastaud L; Ojeda-Uribe M; Boscagli A; Caruso S; Skaf R; Gutnecht J; Thyss A; Peyrade F
    Exp Hematol Oncol; 2015; 4():18. PubMed ID: 26185733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma.
    Kim DY; Chung JS; Jo JC; Cho SH; Shin HJ
    Ann Hematol; 2020 Apr; 99(4):819-828. PubMed ID: 32025840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
    Shabbir-Moosajee M; Jehangir S; Sawani S; Muhammed T; Ali N; Sheikh U; Adil S
    Blood Res; 2019 Jun; 54(2):108-113. PubMed ID: 31309088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma.
    Solomon SR; Brown S; Shegda N; Jackson KC; Zhang X; Bashey A; Holland HK; Morris LE; Solh M
    Transplant Cell Ther; 2022 Aug; 28(8):486.e1-486.e7. PubMed ID: 35598842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.
    Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F
    Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.
    Visani G; Malerba L; Stefani PM; Capria S; Galieni P; Gaudio F; Specchia G; Meloni G; Gherlinzoni F; Giardini C; Falcioni S; Cuberli F; Gobbi M; Sarina B; Santoro A; Ferrara F; Rocchi M; Ocio EM; Caballero MD; Isidori A
    Blood; 2011 Sep; 118(12):3419-25. PubMed ID: 21816830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lomustine, cytarabine, cyclophosphamide, etoposide - An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors.
    Gupta A; Gokarn A; Rajamanickam D; Punatar S; Thippeswamy R; Mathew L; Bagal B; Kannan S; Khattry N
    J Cancer Res Ther; 2018; 14(5):926-933. PubMed ID: 30197327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and toxicity of SEAM (semustine, etoposide, cytarabine, and melphalan) conditioning regimen followed by autologous stem cell transplantation in lymphoma.
    Zhang L; Yang H; Qian C; Zhou J; Zhu Q; Jiang Y; Liu S; Chen X; Xu T; Qu C; Li C; Jin Z; Chu J; Zhang X; Wu D; Huang H
    Hematology; 2022 Dec; 27(1):404-411. PubMed ID: 35413224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol.
    Ramzi M; Mohamadian M; Vojdani R; Dehghani M; Nourani H; Zakerinia M; Haghighinejad H
    Exp Clin Transplant; 2012 Apr; 10(2):163-7. PubMed ID: 22432762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: A retrospective single-center study.
    AlJohani NI; Nasani M; Ahmed HE; Ur Rehman J; Nawaz A; Alzahrani Z; Albeirouti B
    Hematol Oncol Stem Cell Ther; 2021 Dec; 14(4):327-335. PubMed ID: 33306964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
    Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
    Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.
    Noesslinger T; Panny M; Simanek R; Moestl M; Boehm A; Menschel E; Koller E; Keil F
    Eur J Haematol; 2018 Sep; 101(3):326-331. PubMed ID: 29799642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma.
    Lin M; Wu X; Zhang L; Li L; Wang X; Fu X; Sun Z; Zhang X; Zhu L; Yu H; Chang Y; Nan F; Yan J; Zhou Z; Shi C; Zhang M; Li X
    Leuk Lymphoma; 2023 Mar; 64(3):605-612. PubMed ID: 36657436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers.
    Chantepie SP; Garciaz S; Tchernonog E; Peyrade F; Larcher MV; Diouf M; Fornecker LM; Houot R; Gastinne T; Soussain C; Malak S; Lemal R; Delette C; Ibrahim A; Gac AC; Reboursière E; Vilque JP; Bekadja MA; Casasnovas RO; Gressin R; Guidez S; Coso D; Herbaux C; Yakoub-Agha I; Bouabdallah K; Durot E; Damaj G
    Am J Hematol; 2018 Jun; 93(6):729-735. PubMed ID: 29473209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
    Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
    Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.